Abstract
Background Cell-free DNA (cfDNA), a broadly applicable biomarker commonly sourced from urine or blood, is extensively used for research and diagnostic applications. In various settings, genetic and epigenetic information is derived from cfDNA. However, a unified framework for its processing is lacking, limiting the universal application of innovative analysis strategies and the joining of data sets.
Findings Here, we describe cfDNA UniFlow, a unified, standardized, and ready-to-use workflow for processing cfDNA samples. The workflow is written in Snakemake and can be scaled from stand -alone computers to cluster environments. It includes methods for processing raw genome sequencing data as well as specialized approaches for correcting sequencing errors, filtering, and quality control. Sophisticated methods for detecting copy number alterations and estimating and correcting GC-related biases are readily incorporated. Furthermore, it includes methods for extracting, normalizing and visualizing coverage signals around user defined regions in case-control settings. Ultimately, all results and metrics are aggregated in a unified report, enabling easy access to a wide variety of information for further research and downstream analysis.
Conclusions We provide an automated pipeline for processing cell-free DNA sampled from liquid biopsies, including a wide variety of additional functionalities like bias correction and signal extraction. With our focus on scalability and extensibility, we provide a foundation for future cfDNA research and faster clinical applications.
Issue Section Technical Note
Availability and implementation Source code and extensive documentation is available on our GitHub repository (https://github.com/kircherlab/cfDNA-UniFlow).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Berlin Institute of Health at Charite Universitaetsmedizin Berlin (to M.K.); Deutsche Forschungsgemeinschaft (DFG) [355312821 to S.R.].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵‡ Deceased on Sep 24, 2023
Contact: martin.kircher@bih-charite.de
Data Availability
The data used for generating plots included in this article are available in the European Genome-Phenome Archive at https://ega-archive.org with accession EGAD00001010100.
Abbreviations
- BAM
- binary alignment map
- cfDNA
- cell-free DNA
- CNA
- copy number alteration
- ctDNA
- circulating tumor DNA
- TF
- transcription factor
- QC
- quality control
